Newer anti–PD-1 agents introduced in recent years seem to follow the same trend, as patients with NSCLC with brain metastases experienced improved cognitive function and HRQL scores over time during treatment with camrelizumab (PD-1 inhibitor) plus chemotherapy [18]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.